Canaan Announces General Partners
This article was originally published in Scrip
Canaan Partners has appointed Nina Kjellson general partner and has promoted Hrach Simonian to the same position in the firm's technology practice. Healthcare investor, Kjellson was general partner at InterWest Partners for 13 years, where she was involved with over 24 investments and delivered numerous successful exits. Currently Kjellson is director of three biotech firms including Lycera Corp, Eiger Biopharma, Ocera Therapeutics and of a healthcare focused software company Welltok Inc. Simonian was previously an investor at Canaan and helped grow its West Coast technology practices and also led the VC's investment in Instacart. He serves on the board of Cargomatic, Realty Mogul, CompStak and Washio.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.